Sign Up Today and Learn More About Verismo Therapeutics Stock
Invest in or calculate the value of your shares in Verismo Therapeutics or other pre-IPO companies through EquityZen's platform.
Verismo Therapeutics Stock (VETH)
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
About Verismo Therapeutics Stock
Founded
2020
Headquarters
Philadelphia, PA, US
Industries
Science and Engineering, Health Care, Biotechnology
Verismo Therapeutics Press Mentions
Stay in the know about the latest news on Verismo Therapeutics
Verismo Therapeutics Awarded a ScaleReady™ G-Rex® Grant
prnewswire • Sep 17, 2024
Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024
biospace • Aug 03, 2024
Verismo Therapeutics Receives IND Clearance from the FDA for SynKIR™-310 in Relapsed/Refractory B-cell NHL
prnewswire • Jun 05, 2024
Verismo Therapeutics Announces Upcoming Presentation at ASGCT 2024
prnewswire • Jun 05, 2024
Verismo's Synkir-310 receives FDA clearance for phase I trial in NHL
bioworld • May 20, 2024
Verismo Therapeutics Management
Leadership team at Verismo Therapeutics
Director of Corporate Development
Pavel Aprelev
Co-Founder, Co-Chairman of Scientific Advisory Board
Michael C. Milone
Join now and verify your accreditation status to gain access to:
- Verismo Therapeutics Current Valuation
- Verismo Therapeutics Stock Price
- Verismo Therapeutics Management
- Available deals in Verismo Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Verismo Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Verismo Therapeutics Revenue and Financials
- Verismo Therapeutics Highlights
- Verismo Therapeutics Business Model
- Verismo Therapeutics Risk Factors
- Verismo Therapeutics Research Report from SACRA Research
Trading Verismo Therapeutics Stock
How to invest in Verismo Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Verismo Therapeutics through EquityZen funds. These investments are made available by existing Verismo Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Verismo Therapeutics stock?
Shareholders can sell their Verismo Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."